Medicare Part D Claims for GLP-1s (CY 2018 to 2022) The expanded indication for Wegovy is expected to increase spending on this medication class
This ensures the capsule dissolves and the peptide is released into a less aggressive gastric environment, allowing it to pass into the small intestine for absorption with minimal degradation
Athletic performance and endurance formulas
In November 2023, the FDA granted approval for Zepbound (tirzepatide) for chronic weight management in adults with obesity (body mass index 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbid condition such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease
* Contains Milk
Addressing modifiable comorbidities such as alcohol use, metabolic disease, sleep disturbances, and psychiatric conditions may improve pain while simultaneously altering the trajectory of liver disease